Current treatments

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Leiba M et al. Br J Haematol. 2014 May 26. doi: 10.1111/bjh.12946. [Epub ahead of print]. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for newly diagnosed myeloma multiple patients. Blanes M…

Details

Related conditions

Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Vrana JA et al. Haematologica. 2014 Apr 18. [Epub ahead of print]. A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. Sorigue M et al. Cytometry B Clin Cytom. 2014 Apr 9. doi: 10.1002/cyto.b.21173. [Epub ahead of print]. A rare cause…

Details

General

United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. Rabin N et al. Int J Lab Hematol. 2014 Mar 27. doi: 10.1111/ijlh.12205. [Epub ahead of print]. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow…

Details

Emerging treatments

Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.Donato F et al. Expert Opin Biol Ther. 2014 Apr 21. [Epub ahead of print].Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Yee AJ et al. Br J Haematol. 2014 Apr 25. doi:…

Details

Biology and genetics

Jumping translocations and high-risk myeloma. Morgan GJ et al. Blood. 2014 Apr 17;123(16):2442-3. doi: 10.1182/blood-2014-02-555755. NF-Kappa B Modulation Is Involved in Celastrol Induced Human Multiple Myeloma Cell Apoptosis. Ni H et al. PLoS One. 2014 Apr 22;9(4):e95846. doi: 10.1371/journal.pone.0095846. eCollection 2014. Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple…

Details

Supportive care

Advances in supportive care for multiple myeloma.Raje NS et al. J Natl Compr Canc Netw. 2014 Apr 1;12(4):502-11.Surgical management of primary tumors of the cervical spine: surgical considerations and avoidance of complications.Kaloostian PE et al. Neurol Res. 2014 Apr 10:1743132814Y0000000367. [Epub ahead of print].Post-operative Cement Augmentation after 360-degree Fusion for Highly Unstable Vertebral Fractures in…

Details

Complications of myeloma and its treatments

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Jackson GH et al. Br J Haematol. 2014 Mar 27. doi: 10.1111/bjh.12861. [Epub ahead of print]. Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. Wanchoo R et al. J Oncol Pharm Pract. 2014…

Details

Current treatments

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.Mateos MV et al. Haematologica. 2014 Apr 24. [Epub ahead of print].Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.Ahn SY et…

Details